May 12, 2026 08:05 ET  | Source: Boehringer Ingelheim Limited Ingelheim, Germany and Waltham, Mass., U.S., May X, 2026 – Boehringer Ingelheim and Immunitas Therapeutics today announced a global licensing agreement for a preclinical antibody program being developed for chronic inflammatory and autoimmune diseases. The program is designed to selectively target cells that play a central role in

May 11, 2026 21:32 ET  | Source: Enlitic LOVELAND, Colo., May 11, 2026 (GLOBE NEWSWIRE) — Enlitic, a global leader in radiology and imaging data, today announced the successful go-live of its Ensight platform at RHCNZ Medical Imaging Group (RHCNZ), New Zealand’s largest private radiology provider. The deployment marks Enlitic’s first customer in New Zealand and represents

May 11, 2026 08:00 ET  | Source: AskBio Inc. (AskBio) Durham, N.C., May 11, 2026 (GLOBE NEWSWIRE) — AskBio Inc. (AskBio), a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG, today announced that the first participant has been dosed with investigational gene therapy AB-1009 as part of PROGRESS-GT LOPD, a Phase 1/Phase 2 clinical trial in participants with late-onset Pompe disease (LOPD).  LOPD

May 11, 2026 07:00 ET  | Source: Dark Horse Consulting Group WALNUT CREEK, Calif., May 11, 2026 (GLOBE NEWSWIRE) — Dark Horse Consulting Group (“DHCG” or “the Group”), a leader in strategic and operational biotherapeutics consulting, and KunTuo Medical Research and Development (Beijing) Co., Ltd. (“KunTuo”), a full-service contract research organization (CRO) dedicated to clinical research services

May 11, 2026 05:00 ET  | Source: BASF Agricultural Solutions Ludwigshafen, Germany, May 11, 2026 – BASF Agricultural Solutions has successfully commissioned its BioHub, a new fermentation plant for biological and biotechnology-based crop protection products, at the Ludwigshafen site. With an investment in the high double-digit million-euro range, BASF is strengthening its portfolio of biological innovations. The

May 08, 2026 09:01 ET  | Source: Royal Philips May 8, 2026 Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced that its shareholders approved all proposals at the Annual General Meeting of Shareholders (AGM) 2026, including: Feike Sijbesma, Chairman of Philips’ Supervisory Board, said: “On behalf of the Supervisory Board

May 07, 2026 02:14 ET  | Source: Angelini Pharma; Catalyst Pharmaceuticals ROME and CORAL GABLES, Fla., May 07, 2026 (GLOBE NEWSWIRE) — Angelini Pharma S.p.A. (“Angelini Pharma”), an international pharmaceutical company and part of the Angelini Industries Group, and Catalyst Pharmaceuticals, Inc. (“Catalyst”) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with

May 06, 2026 12:04 ET  | Source: CARBOGEN AMCIS INNOVATIONS AG BUBENDORF, Switzerland, May 06, 2026 (GLOBE NEWSWIRE) — CARBOGEN AMCIS, a Switzerland-based pharmaceutical process development and Active Pharmaceutical Ingredient (API) manufacturing company, today announces its Shanghai facility has successfully completed an unannounced Good Manufacturing Practice (GMP) inspection by China’s National Medical Products Administration (NMPA), with no observations.

May 06, 2026 01:00 ET  | Source: Royal Philips May 6, 2026 Q1 2026 Group performance Roy Jakobs, CEO of Royal Philips:“We delivered a good start to 2026, with strong order intake growth at 6%, comparable sales growth of 4% and margin expansion of 40 basis points, reflecting disciplined execution against our plan in an uncertain macro-environment.

May 05, 2026 13:00 ET  | Source: Smith & Nephew UK Ltd Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, continues to drive progress in chronic wound management with an industry-leading portfolio set to showcase at the upcoming European Wound Management Association (EWMA) Conference, Bremen between 6-8 May 2026. Demonstrating a long-term commitment to chronic wound management,

May 05, 2026 09:03 ET  | Source: SK pharmteco Inc. RANCHO CORDOVA, Calif., May 05, 2026 (GLOBE NEWSWIRE) — SK pharmteco announced today that its greenhouse gas (GHG) emissions reduction targets have been officially validated by the Science Based Targets initiative (SBTi). This approval confirms that SK pharmteco’s sustainability roadmap aligns with the strict 1.5°C pathway required to fight global climate

May 05, 2026 06:03 ET  | Source: Ingredion Incorporated WESTCHESTER, Ill., May 05, 2026 (GLOBE NEWSWIRE) — Ingredion Incorporated (NYSE: INGR), a leading global provider of ingredient solutions to the food and beverage manufacturing industry, today reported its first quarter 2026 results. “While we expected a challenging first quarter after last year’s strong first quarter, results were

May 04, 2026 16:30 ET  | Source: Teva Pharmaceutical Industries Ltd PARSIPPANY, N.J., and TEL AVIV, Israel, May 04, 2026 (GLOBE NEWSWIRE) — Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Eric Hughes, Teva’s EVP of Global R&D & Chief Medical Officer, will present at the BofA Securities Health Care Conference on Tuesday, May

May 04, 2026 08:00 ET  | Source: Dr. Falk Pharma FREIBURG, Germany and ROSCREA, Ireland – May 4, 2026 – Dr. Falk Pharma GmbH (“Dr. Falk Pharma”), a research-based pharmaceutical company specializing in digestive and metabolic medicine, and Renexxion Ireland Limited (“Renexxion”), a clinical-stage biopharmaceutical company, today announced positive results from MOVE-IT (NCT05621811), a global Phase 2b, randomized

April 30, 2026 15:07 ET  | Source: EnGeneIC SYDNEY, May 01, 2026 (GLOBE NEWSWIRE) — EnGeneIC Limited today announced that the first patient has been dosed in its clinical trial evaluating EnGeneIC’s investigational EGFR-targeted EDV™ (EnGeneIC Dream Vector) therapy in patients with recurrent glioblastoma multiforme (GBM), an aggressive and currently incurable form of brain cancer. The trial